IFNG and tuberculosis: Recombinant IFN-γ treatment is used to prevent infection in patients with chronic granulomatous disease (CGD), albeit with negative side effects (flu-like symptoms); its efficacy as an adjunct TB therapy has also been tested in small clinical trials, with positive results (27).